Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mizagliflozin in Post-Bariatric Hypoglycemia
NCT07760961Phase 2Recruiting
- Sponsor
- Vogenx
- Start
- Oct 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mizagliflozin in post-bariatric hypoglycemia (PBH) (3 arms), sponsored by Vogenx. Primary endpoint: Number of combined Level 2 and Level 3 hypoglycemic events at 28 days. Started Oct 2026; status: recruiting.
02
Drugs
mizagliflozin
03
Conditions
post-bariatric hypoglycemia (PBH)
Beyond the preview
Go deeper on NCT07760961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07760961.